Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constance Thibault

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
European Urology Oncology|June 24, 2026
Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer TrialsPietro Scilipoti, Aleksander Ślusarczyk, Constance Thibault, et al.
European Urology Oncology|September 16, 2020
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic ReviewGiancarlo Marra, Massimo Valerio, Isabel Heidegger, et al.
European Urology Oncology|July 19, 2022
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell CarcinomaGéraldine Pignot, Antoine Thiery-Vuillemin, Laurence Albigès, et al.
European Urology Oncology|October 24, 2024
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line TreatmentPhilippe Barthélémy, Constance Thibault, Aude Fléchon, et al.
World Journal of Urology|January 3, 2025
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinomaGeraldine Pignot, Gaelle Margue, Pierre Bigot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO StudyConstance Thibault, Mostefa Bennamoun, Aude Fléchon, et al.
European Urology Oncology|April 22, 2025
Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT StudyDoriane Prost, Atanas Pachev, Eric De Kerviler, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 studyLoïc Mourey, Larissa Tames Rainho, Cécile Dalban, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Response to systemic therapy in fumarate hydratase-deficient renal cell carcinomaLucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2026
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
European Urology Oncology|June 24, 2026
Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer TrialsPietro Scilipoti, Aleksander Ślusarczyk, Constance Thibault, et al.
European Urology Oncology|September 16, 2020
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic ReviewGiancarlo Marra, Massimo Valerio, Isabel Heidegger, et al.
European Urology Oncology|July 19, 2022
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell CarcinomaGéraldine Pignot, Antoine Thiery-Vuillemin, Laurence Albigès, et al.
European Urology Oncology|October 24, 2024
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line TreatmentPhilippe Barthélémy, Constance Thibault, Aude Fléchon, et al.
World Journal of Urology|January 3, 2025
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinomaGeraldine Pignot, Gaelle Margue, Pierre Bigot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO StudyConstance Thibault, Mostefa Bennamoun, Aude Fléchon, et al.
European Urology Oncology|April 22, 2025
Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT StudyDoriane Prost, Atanas Pachev, Eric De Kerviler, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 studyLoïc Mourey, Larissa Tames Rainho, Cécile Dalban, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Response to systemic therapy in fumarate hydratase-deficient renal cell carcinomaLucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2026
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.
Pageof 11